PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11334412-7	2001	These results indicate that the ability of pioglitazone to restore insulin-stimulated tyrosine phosphorylation of IR/IRS-1, which is necessary for amelioration of TNF-alpha-induced insulin resistance, may be independent of the adipogenic activity of PPAR-gamma that regulates protein levels of IR/IRS-1.	Pioglitazone	43-55	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	250-260	
21514306-1	2011	AIMS: Pioglitazone, a full peroxisome proliferator-activated receptor (PPAR)-gamma agonist, improves insulin sensitivity by increasing circulating adiponectin levels.	Pioglitazone	6-18	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	27-82	
21514306-9	2011	In addition, adenovirus-mediated PPARgamma expression significantly enhanced the effects of pioglitazone on insulin-stimulated 2-DOG uptake and AdipoR2 expression in 3T3-L1 adipocytes.	Pioglitazone	92-104	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	33-42	
21514306-10	2011	These data suggest that pioglitazone enhances adiponectin"s autocrine and paracrine actions in 3T3-L1 adipocytes via upregulation of PPARgamma-mediated AdipoR2 expression.	Pioglitazone	24-36	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	133-142	
21514306-12	2011	SIGNIFICANCE: Our results suggest that pioglitazone increases insulin sensitivity, at least partly, by PPARgamma-AdipoR2-mediated AMPK phosphorylation in 3T3-L1 adipocytes.	Pioglitazone	39-51	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	103-112	
30116202-8	2018	However, klotho expression was increased by pioglitazone, an agonist of PPAR-gamma, and suppressed by BADGE, an antagonist of PPAR-gamma, suggesting that the effect of Ang II downregulating klotho is mediated by PPAR-gamma.	Pioglitazone	44-56	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	72-82	
17599749-0	2007	The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways.	Pioglitazone	61-73	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	4-52	
17599749-2	2007	The aim of this study was to evaluate the in vivo effect of a PPARgamma agonist, pioglitazone, on the development of lesions in a canine model of OA, and to explore the influence of pioglitazone on the major signaling and metabolic pathways involved in OA pathophysiologic changes.	Pioglitazone	81-93	peroxisome proliferator activated receptor gamma	Canis lupus familiaris	62-71